The follicle stimulating hormone market size is expected to see steady growth in the next few years. It will grow to $2.49 billion in 2028 at a compound annual growth rate (CAGR) of 5.0%. The anticipated growth in the forecast period can be ascribed to the broadening of therapeutic applications, an increasing demand for combination therapy, a rising need for effective contraceptive options, the aging population and its associated healthcare requirements, and the expansion of the market in key regions. Major trends expected in the forecast period include the development of advanced biosimilar FSH products, regulatory approvals and market access, technological advancements in FSH production and delivery, and an increasing demand for effective contraceptive options.
The anticipated growth in the follicle-stimulating hormone market is expected to be propelled by the increasing prevalence of infertility. Infertility, a condition impacting the male or female reproductive system, is characterized by the inability to conceive after 12 months or more of frequent, unprotected sexual contact. Follicle-stimulating hormone plays a crucial role in encouraging egg development in the ovaries and regulating the menstrual cycle in females. In men, it promotes testicular growth and assists in the production of a protein essential for male fertility by supporting the development of healthy sperm cells. Notably, as of April 2023, the World Health Organization reported that infertility affected approximately 1 in 6 adults globally, accounting for around 17.5% of the adult population. Moreover, data from the Australian Bureau of Statistics in October 2023 indicated a 3% decrease in recorded births in 2022, with an overall fertility rate of 1.63 births per woman. Consequently, the increasing prevalence of infertility is a driving force behind the growth of the follicle-stimulating hormone market.
The rising adoption of assisted reproductive technology is also anticipated to contribute to the growth of the follicle-stimulating hormone market in the foreseeable future. Assisted Reproductive Technology (ART) encompasses medical procedures or practices designed to assist individuals or couples in conceiving when conventional methods prove ineffective. The use of follicle-stimulating hormone in assisted reproductive technology is a well-established therapy aimed at enhancing the chances of a successful pregnancy for individuals or couples facing reproductive challenges. Notably, the CDC’s 2021 Fertility Clinic Success Rates Report, released by the Centers for Disease Control and Prevention in September 2023, revealed that approximately 238,126 individuals underwent 413,776 ART cycles at 453 registered clinics in the United States in 2021. These procedures resulted in 91,906 live births and 97,128 live-born infants. Therefore, the increasing adoption of assisted reproductive technology is a key driver for the follicle-stimulating hormone market.
Product innovations emerge as a prominent trend gaining traction in the follicle-stimulating hormone market. Major players in the market are strategically focusing on the development of innovative products to fortify their positions. For example, in August 2021, Merck Specialties Pvt. Ltd., a healthcare company based in India, introduced the Pergoveris Pen as part of efforts to enhance infertility treatment options. The Pergoveris Pen stands out as an innovative device that integrates recombinant follicle-stimulating hormone (FSH) and recombinant luteinizing hormone (LH) in a convenient, pre-filled format. Notably, it is the first pen injector to combine these hormones. Tailored for prescribed use by in vitro fertilization (IVF) specialists, the Pergoveris Pen provides a combination treatment solution specifically designed for women experiencing severe deficiencies in FSH and LH.
Major companies in the follicle-stimulating hormone market are also investing in the development of groundbreaking products such as estrogen-based pills to augment their product offerings and gain a competitive edge. Estrogen-based pills, containing the essential hormone for the growth and management of the female reproductive system, represent a notable innovation. In August 2022, Myovant Sciences Ltd., a UK-based biopharmaceutical company, and Pfizer Inc., a US-based pharmaceutical and biotechnology firm, announced the US Food and Drug Administration (FDA) authorization for MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill treatment. MYFEMBREE serves as a once-daily medication for the treatment of moderate to severe pain caused by endometriosis in premenopausal women for up to 24 months. Additionally, it is authorized for premenopausal women experiencing excessive menstrual bleeding due to uterine fibroids. Myovant and Pfizer intend to jointly market MYFEMBREE in the United States.
In November 2021, Organon, a healthcare company based in the United States, completed the acquisition of Forendo Pharma, a clinical-stage drug development company based in Finland, for an undisclosed amount. This acquisition is expected to enhance Organon's portfolio of women's health treatments, particularly in the domain of follicle-stimulating hormones.
Major companies operating in the follicle stimulating hormone market report are Pfizer Inc., Novartis AG, Abbott Laboratories, Sanofi S.A., Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Cipla Ltd., Ferring Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Livzon Pharmaceutical Group Inc., Emcure Pharmaceuticals Ltd., LG Chem's life sciences, IBSA Group, Bharat Serums and Vaccines Limited, Nihon Kohden Corp., Anhui Anke Biotechnology Group Co. Ltd., Taj Pharmaceuticals Ltd., Genpharm Inc., Cadwell Laboratories Inc., Creative BioMart, Electrical Geodesics Inc., Lee Biosolutions Inc., Trumac Healthcare, Midas Pharma GmbH, Biogenix Inc. Pvt. Ltd., Shanghai Techwell Biopharmaceutical Co. Ltd.
North America was the largest region in the follicle stimulating hormone market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the follicle stimulating hormone market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the follicle stimulating hormone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The primary types of follicle-stimulating hormones include recombinant FSH and urinary FSH. Recombinant FSH is a form of FSH produced using recombinant DNA technology, as opposed to being derived from natural sources such as urine. These hormones find application in various areas, including infertility treatment, assisted reproductive technology (ART), and other medical contexts. They are utilized by diverse end-users, including infertility centers, hospitals, and similar institutions.
The follicle stimulating hormone market research report is one of a series of new reports that provides follicle stimulating hormone market statistics, including follicle stimulating hormone industry global market size, regional shares, competitors with a follicle stimulating hormone market share, detailed follicle stimulating hormone market segments, market trends and opportunities, and any further data you may need to thrive in the follicle stimulating hormone industry. This follicle stimulating hormone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The follicle-stimulating hormone market consists of sales of luteinizing hormone (LH), chorionic gonadotropin (CG), and thyroid-stimulating hormone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Follicle Stimulating Hormone Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on follicle stimulating hormone market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for follicle stimulating hormone? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Type: Recombinant FSH; Urinary FSH
2) By Application: Infertility Treatment; Assisted Reproductive Technology (ART); Other Applications
3) By End-Users: Infertility Center; Hospitals; Other End-Users
Key Companies Mentioned: Pfizer Inc.; Novartis AG; Abbott Laboratories; Sanofi S.A.; Boehringer Ingelheim GmbH
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Pfizer Inc.
- Novartis AG
- Abbott Laboratories
- Sanofi S.A.
- Boehringer Ingelheim GmbH
- Merck KGaA
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Cipla Ltd.
- Ferring Pharmaceuticals Inc.
- Lupin Limited
- Zydus Lifesciences Limited
- Livzon Pharmaceutical Group Inc.
- Emcure Pharmaceuticals Ltd.
- LG Chem's life sciences
- IBSA Group
- Bharat Serums and Vaccines Limited
- Nihon Kohden Corp.
- Anhui Anke Biotechnology Group Co. Ltd.
- Taj Pharmaceuticals Ltd.
- Genpharm Inc.
- Cadwell Laboratories Inc.
- Creative BioMart
- Electrical Geodesics Inc.
- Lee Biosolutions Inc.
- Trumac Healthcare
- Midas Pharma GmbH
- Biogenix Inc. Pvt. Ltd.
- Shanghai Techwell Biopharmaceutical Co. Ltd.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | February 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 2.05 Billion |
Forecasted Market Value ( USD | $ 2.49 Billion |
Compound Annual Growth Rate | 5.0% |
Regions Covered | Global |
No. of Companies Mentioned | 30 |